Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 3, 2026, 7:32 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 28 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: RDX5791 Clear all
Completed Phase 3 Interventional Results available

An 8-Week Study to Evaluate Tenapanor in the Treatment of Hyperphosphatemia in End-Stage Renal Disease Patients on Hemodialysis (ESRD-HD)

NCT02675998
View directory record Official record
Conditions
Hyperphosphatemia
Interventions
Tenapanor, Placebo
Drug
Lead sponsor
Ardelyx
Industry
Eligibility
18 Years to 80 Years
Enrollment
219 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
32
States / cities
Huntsville, Alabama • Riverside, California • Denver, Colorado + 28 more
Source: ClinicalTrials.gov public record
Updated Aug 9, 2020 · Synced Sep 3, 2026, 7:32 PM EDT
Completed Phase 4 Interventional Results available

Study to Evaluate the Use of Tenapanor as Core Therapy in the Treatment of Hyperphosphatemia

NCT04549597
View directory record Official record
Conditions
Chronic Kidney Disease Requiring Chronic Dialysis, Hyperphosphatemia
Interventions
Tenapanor
Drug
Lead sponsor
Ardelyx
Industry
Eligibility
18 Years to 90 Years
Enrollment
333 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Lauderdale Lakes, Florida
Source: ClinicalTrials.gov public record
Updated Mar 28, 2023 · Synced Sep 3, 2026, 7:32 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

To Assess the Effect of AZD1722 on the Pharmacokinetics of Cefadroxil in Healthy Volunteers

NCT02140281
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Treatment A (cefadroxil alone), Treatment B - AZD1722 followed by cefadroxil
Drug
Lead sponsor
Ardelyx
Industry
Eligibility
18 Days to 50 Years
Enrollment
71 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Sep 21, 2015 · Synced Sep 3, 2026, 7:32 PM EDT
Completed Phase 3 Interventional Results available

A 12-Week Study With a 4-Week Randomized Withdrawal Period to Evaluate the Efficacy and Safety of Tenapanor for the Treatment of IBS-C

NCT02621892
View directory record Official record
Conditions
Constipation Predominant Irritable Bowel Syndrome
Interventions
Tenapanor, Placebo
Drug
Lead sponsor
Ardelyx
Industry
Eligibility
18 Years to 75 Years
Enrollment
606 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
111
States / cities
Birmingham, Alabama • Huntsville, Alabama • Chandler, Arizona + 92 more
Source: ClinicalTrials.gov public record
Updated Apr 20, 2020 · Synced Sep 3, 2026, 7:32 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase 1 Study to Examine the Pharmacodynamics of Different AZD1722 Formulations

NCT02249936
View directory record Official record
Conditions
Healthy
Interventions
AZD1722, Omeprazole
Drug
Lead sponsor
Ardelyx
Industry
Eligibility
19 Years to 65 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Sep 25, 2014 · Synced Sep 3, 2026, 7:32 PM EDT
Completed Phase 2Phase 3 Interventional Results available

The Efficacy of AZD1722 in Constipation Predominant Irritable Bowel Syndrome (IBS-C)

NCT01923428
View directory record Official record
Conditions
Constipation Predominant Irritable Bowel Syndrome
Interventions
AZD1722, Placebo
Drug
Lead sponsor
Ardelyx
Industry
Eligibility
18 Years to 75 Years
Enrollment
356 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
4
States / cities
Boulder, Colorado • Greensboro, North Carolina • Winston-Salem, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 7, 2020 · Synced Sep 3, 2026, 7:32 PM EDT
Recruiting Phase 2 Interventional

Tenapanor in Synucleinopathy-Related Constipation

NCT06460038
View directory record Official record
Conditions
Synucleinopathy, Parkinson's Disease
Interventions
Tenapanor, Placebo
Drug
Lead sponsor
Cedar Valley Digestive Health Center
Other
Eligibility
50 Years to 89 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Waterloo, Iowa
Source: ClinicalTrials.gov public record
Updated Feb 9, 2025 · Synced Sep 3, 2026, 7:32 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

An Open-label Study to Evaluate the Pharmacokinetics of Oral Tenapanor in Breast Milk of Lactating Females

NCT06203444
View directory record Official record
Conditions
Lactation
Interventions
Tenapanor
Drug
Lead sponsor
Ardelyx
Industry
Eligibility
18 Years to 60 Years · Female only
Enrollment
7 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
2
States / cities
Oklahoma City, Oklahoma • Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jul 10, 2024 · Synced Sep 3, 2026, 7:32 PM EDT
Enrolling by invitation Phase 3 Interventional

Safety Study of Tenapanor for the Treatment of Pediatric Patients (6 to Less Than 18 Years Old) With IBS-C

NCT05905926
View directory record Official record
Conditions
Irritable Bowel Syndrome With Constipation (IBS-C)
Interventions
Tenapanor
Drug
Lead sponsor
Ardelyx
Industry
Eligibility
6 Years to 18 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2031
U.S. locations
27
States / cities
Foley, Alabama • Anaheim, California • Doral, Florida + 24 more
Source: ClinicalTrials.gov public record
Updated Jun 3, 2026 · Synced Sep 3, 2026, 7:32 PM EDT
Completed Phase 3 Interventional Results available

A Long-Term Safety Study of Tenapanor for the Treatment of IBS-C

NCT02727751
View directory record Official record
Conditions
Constipation Predominant Irritable Bowel Syndrome
Interventions
Tenapanor
Drug
Lead sponsor
Ardelyx
Industry
Eligibility
18 Years to 75 Years
Enrollment
312 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Sep 8, 2020 · Synced Sep 3, 2026, 7:32 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

To Evaluate the Effect of AZD1722 on the Pharmacokinetics of Oral Midazolam in Healthy Volunteers

NCT02140268
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Midazolam, AZD1722, AZD1722 and Midazolam
Drug
Lead sponsor
Ardelyx
Industry
Eligibility
18 Years to 50 Years
Enrollment
65 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Sep 21, 2015 · Synced Sep 3, 2026, 7:32 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Study to Evaluate the Efficacy of Tenapanor as Adjunctive Therapy to Phosphate Binder Therapy

NCT03824587
View directory record Official record
Conditions
Hyperphosphatemia
Interventions
Tenapanor, Placebo, Phosphate Binder Agents
Drug
Lead sponsor
Ardelyx
Industry
Eligibility
18 Years to 80 Years
Enrollment
236 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
48
States / cities
Huntsville, Alabama • Pine Bluff, Arkansas • Beverly Hills, California + 41 more
Source: ClinicalTrials.gov public record
Updated Mar 5, 2023 · Synced Sep 3, 2026, 7:32 PM EDT
Completed Phase 4 Interventional Results available

A Long-Term Study of Tenapanor Alone or in Combination With Sevelamer in Patients With CKD on Dialysis and HP

NCT03988920
View directory record Official record
Conditions
Hyperphosphatemia, End Stage Renal Disease
Interventions
Tenapanor, Sevelamer Carbonate
Drug
Lead sponsor
Ardelyx
Industry
Eligibility
Not listed
Enrollment
172 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Houston, California
Source: ClinicalTrials.gov public record
Updated Mar 28, 2023 · Synced Sep 3, 2026, 7:32 PM EDT
Completed Phase 2 Interventional Results available

Dose Finding Study to Treat High Phosphate Levels in the Blood.

NCT02081534
View directory record Official record
Conditions
Hyperphosphatemia
Interventions
AZD1722, Placebo
Drug
Lead sponsor
Ardelyx
Industry
Eligibility
18 Years to 85 Years
Enrollment
162 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
16
States / cities
Downey, California • Los Angeles, California • Sacramento, California + 13 more
Source: ClinicalTrials.gov public record
Updated Sep 13, 2020 · Synced Sep 3, 2026, 7:32 PM EDT
Recruiting Phase 3 Interventional

A 26-Wk Study to Assess Safety & Efficacy of Tenapanor for T/t of Chronic Idiopathic Constipation in Adults

NCT07382167
View directory record Official record
Conditions
Chronic Idiopathic Constipation (CIC)
Interventions
Tenapanor 5 mg BID, Tenapanor 25 mg BID, Tenapanor 50 mg BID, Placebo
Drug
Lead sponsor
Ardelyx
Industry
Eligibility
18 Years to 80 Years
Enrollment
692 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
109
States / cities
Foley, Alabama • Saraland, Alabama • Chandler, Arizona + 98 more
Source: ClinicalTrials.gov public record
Updated Jun 3, 2026 · Synced Sep 3, 2026, 7:32 PM EDT
Active, not recruiting Phase 3 Interventional

Study to Assess Safety and Efficacy of Tenapanor for Treatment of IBS-C in Pediatric Patients 12 to Less Than 18 Years

NCT05643534
View directory record Official record
Conditions
Irritable Bowel Syndrome With Constipation (IBS-C)
Interventions
Tenapanor 50 MG, Tenapanor 25 mg bid, Placebo
Drug
Lead sponsor
Ardelyx
Industry
Eligibility
12 Years to 17 Years
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
39
States / cities
Foley, Alabama • Tucson, Arizona • Little Rock, Arkansas + 34 more
Source: ClinicalTrials.gov public record
Updated Jun 3, 2026 · Synced Sep 3, 2026, 7:32 PM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate the Safety and Efficacy of RDX5791 for the Treatment of Constipation Predominant Irritable Bowel Syndrome (IBS-C)

NCT01340053
View directory record Official record
Conditions
Constipation Predominant Irritable Bowel Syndrome
Interventions
RDX5791
Drug
Lead sponsor
Ardelyx
Industry
Eligibility
18 Years to 75 Years
Enrollment
186 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
16
States / cities
San Diego, California • Jupiter, Florida • Pinellas Park, Florida + 13 more
Source: ClinicalTrials.gov public record
Updated Oct 14, 2019 · Synced Sep 3, 2026, 7:32 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

D5611C00003 - Food Interaction Study With AZD1722 Tablet in Healthy Subjects

NCT02226783
View directory record Official record
Conditions
Healthy Volunteers Food Interaction Study
Interventions
AZD1722 salt tablet, AZD1722 free base tablet, AZD1722 free base tablet + Omeprazole
Drug
Lead sponsor
Ardelyx
Industry
Eligibility
18 Years to 65 Years
Enrollment
37 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Sep 21, 2015 · Synced Sep 3, 2026, 7:32 PM EDT
Completed Phase 4 Interventional

Effect of Tenapanor on the Metagenomics and Metabolomics of Patients With Irritable Bowel Syndrome With Constipation

NCT05995899
View directory record Official record
Conditions
IBS, IBS - Irritable Bowel Syndrome
Interventions
Tenapanor
Drug
Lead sponsor
Kyle Staller, MD, MPH
Other
Eligibility
18 Years to 75 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 11, 2026 · Synced Sep 3, 2026, 7:32 PM EDT
Completed Phase 2 Interventional

4-Week, Multi-center Dose-Ranging Study for the IBS-C in Pts. 6 to <12 Yrs

NCT06553547
View directory record Official record
Conditions
Irritable Bowel Syndrome With Constipation (IBS-C)
Interventions
Tenapanor, Placebo
Drug
Lead sponsor
Ardelyx
Industry
Eligibility
6 Years to 11 Years
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
20
States / cities
Little Rock, Arkansas • Hartford, Connecticut • Miami, Florida + 15 more
Source: ClinicalTrials.gov public record
Updated Aug 18, 2026 · Synced Sep 3, 2026, 7:32 PM EDT
Active, not recruiting Phase 3 Interventional

Assessing Tenapanor as a Treatment of CF-related Constipation.

NCT06810167
View directory record Official record
Conditions
Cystic Fibrosis, Constipation
Interventions
Tenapanor
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 75 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 20, 2026 · Synced Sep 3, 2026, 7:32 PM EDT
Completed Phase 3 Interventional Results available

A 26-Week Study to Evaluate the Efficacy and Safety of Tenapanor in IBS-C

NCT02686138
View directory record Official record
Conditions
Constipation Predominant Irritable Bowel Syndrome
Interventions
Tenapanor, Placebo
Drug
Lead sponsor
Ardelyx
Industry
Eligibility
18 Years to 75 Years
Enrollment
593 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
117
States / cities
Dothan, Alabama • Foley, Alabama • Huntsville, Alabama + 98 more
Source: ClinicalTrials.gov public record
Updated Apr 21, 2020 · Synced Sep 3, 2026, 7:32 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase 1 Study to Examine the Effect of Renvela on the Pharmacodynamics of AZD1722

NCT02346890
View directory record Official record
Conditions
Healthy
Interventions
AZD1722, Renvela
Drug
Lead sponsor
Ardelyx
Industry
Eligibility
19 Years to 65 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jan 26, 2015 · Synced Sep 3, 2026, 7:32 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety, Tolerability, Pharmacokinetics and Pharmacodynamic of AZD1722 in Healthy Male and Female Japanese Subjects

NCT02176252
View directory record Official record
Conditions
Healthy Volunteer
Interventions
AZD1722, Placebo
Drug
Lead sponsor
Ardelyx
Industry
Eligibility
19 Years to 65 Years
Enrollment
83 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Cypress, California
Source: ClinicalTrials.gov public record
Updated Jun 26, 2014 · Synced Sep 3, 2026, 7:32 PM EDT